他汀使用与中国人群脑出血风险:目标试验模拟研究
基于鄞州区域医疗数据库2011—2020年数据,采用目标试验模拟方法纳入53,413例他汀起始者与35,033,455例非起始者,经倾向评分匹配后中位随访6.7年,他汀起始者脑出血风险升高(HR 1.18,95%CI 1.03-1.35),全因死亡率降低(HR 0.92,95%CI 0.88-0.97),脑出血相关死亡率无显著差异。
要点
- 中国无脑出血史人群中,他汀起始者脑出血风险升高(HR 1.18,95%CI 1.03-1.35)。
- 他汀起始者全因死亡率降低(HR 0.92,95%CI 0.88-0.97)。
- 脑出血相关死亡率无显著差异(HR 1.16,95%CI 0.91-1.46)。
核心结论
- 他汀使用可能增加中国无脑出血史患者的脑出血风险。
- 本研究提供III级证据表明在中国人群中起始他汀可能增加脑出血风险。
研究设计与样本
- 目标试验模拟研究,使用鄞州区域医疗数据库2011—2020年数据。
- 纳入50岁及以上、无脑出血史且未使用他汀的患者,根据1个月入组期内初始治疗方案分为他汀起始者与非起始者。
- 采用序贯试验方法,2011—2015年每月模拟1个目标试验,共60个模拟试验。
- 每个模拟试验内采用倾向评分匹配平衡两组特征,后将试验堆叠为单一数据集。
- 采用Cox比例风险模型估计他汀对脑出血风险、脑出血相关死亡率和全因死亡率的影响。
主要发现
- 共纳入60个模拟试验中的53,413例他汀起始者和35,033,455例非起始者。
- 他汀起始者较非起始者年龄更大(平均65岁 vs 63岁),男性比例更低(45.5% vs 50.5%),高血压病史比例更高(69.0% vs 14.1%)。
- 倾向评分匹配后两组所有特征均平衡良好。
- 中位随访6.7年(四分位距5.6-8.1年),他汀起始者较非起始者脑出血风险升高(HR 1.18,95%CI 1.03-1.35)。
- 他汀起始者较非起始者脑出血相关死亡率无显著差异(HR 1.16,95%CI 0.91-1.46),全因死亡率降低(HR 0.92,95%CI 0.88-0.97)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为他汀使用可能增加中国无脑出血史患者的脑出血风险。
局限性
- 研究结果可能受残余混杂限制,特别是缺乏胆固醇相关测量指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Statins have been shown to prevent major vascular events in a wide range of individuals. However, their potential mechanisms-such as impairing fibrinogen cleavage and reducing thrombin generation-raise concerns on increased risk of intracerebral hemorrhage (ICH). Given the inconsistent findings of previous trials and observational studies, this study aims to assess the effect of statins on ICH risk in Chinese population. METHODS: Within the framework of target trial emulation, we used data from the Yinzhou Regional Health Care Database covering the years 2011-2020. The study included patients aged 50 years or older with no history of ICH and statin use. After applying inclusion and exclusion criteria, patients were categorized as statin initiators or noninitiators based on their initial treatment regimen during the 1-month enrollment period. Using the sequential trial approach, 60 target trials were emulated each month from 2011 to 2015. Propensity score (PS) matching was applied to balance characteristics between statin initiators and noninitiators within each emulated trial, and these trials were then stacked together into a single data set. Cox proportional hazards models were used to estimate the effects of statin on ICH risk, ICH-related mortality, and all-cause mortality. RESULTS: A total of 53,413 statin initiators and 35,033,455 noninitiators from 60 emulated trials were included in the analysis. Statin initiators were generally older (mean age 65 vs 63 years), less likely to be male (45.5% vs 50.5%), and more likely to have a history of hypertension (69.0% vs 14.1%). After PS matching, all characteristics between the 2 groups were well balanced. With a median follow-up of 6.7 (interquartile range 5.6-8.1) years, the hazard ratio (HR) of ICH for statin initiators compared with noninitiators was 1.18 (95% CI 1.03-1.35). The HRs of ICH-related mortality and all-cause mortality were 1.16 (95% CI 0.91-1.46) and 0.92 (95% CI 0.88-0.97), respectively. Results remained consistent across various subgroup and sensitivity analyses. DISCUSSION: Statin use may increase the risk of ICH in Chinese patients without history of ICH. However, the findings of this study may be limited by residual confounding, particularly the lack of cholesterol-related measurements. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in Chinese populations, initiation of statins may increase the risk of ICH.
引用
- Ji D, Dong S, Wang T, et al. Statin Use and Risk of Intracerebral Hemorrhage in Chinese Population: A Target Trial Emulation Study. Neurology. 2025. PMID: 40146950. doi:10.1212/WNL.0000000000213489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。